Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
Superinvestors holding ADMA, Q2 2026
2 superinvestors report holding Adma Biologics, Inc. on Form 13F, worth $37.1M in total. Weight is Adma Biologics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Duquesne Family OfficeStanley Druckenmiller | 0.5% | 2,784,110 | $23.3M | Added+80.1% |
| FundsmithTerry Smith | 0.1% | 1,649,493 | $13.8M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ADMA each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
2 superinvestors holding at quarter end
- Added
- Duquesne Family Office (+80.1%)
Q1 2026
2 superinvestors holding at quarter end
- Added
- Duquesne Family Office (+512.9%)
- Reduced
- Fundsmith (−21.5%)
Q4 2025
2 superinvestors holding at quarter end